Canaccord raised the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$13 from C$12.50 and keeps a Hold rating on the shares.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPHRF:
- Cipher Pharmaceuticals Reports Strong Revenue Growth in Q1 2025
- Cipher Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Cipher Pharmaceuticals Reports Strong Q1 2025 Results and Strategic Debt Repayment
- CPHRF Upcoming Earnings Report: What to Expect?
- Cipher Pharmaceuticals to Announce Q1 2025 Financial Results